1. Home
  2. BOXL vs GRI Comparison

BOXL vs GRI Comparison

Compare BOXL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boxlight Corporation

BOXL

Boxlight Corporation

HOLD

Current Price

$0.62

Market Cap

3.3M

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$1.87

Market Cap

3.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOXL
GRI
Founded
1985
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
BOXL
GRI
Price
$0.62
$1.87
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
65.9K
76.2K
Earning Date
04-16-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$25,743,612.00
N/A
Revenue This Year
$2.70
N/A
Revenue Next Year
$5.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.37
N/A
52 Week Low
$0.50
$0.18
52 Week High
$10.15
$6.70

Technical Indicators

Market Signals
Indicator
BOXL
GRI
Relative Strength Index (RSI) 32.08 37.63
Support Level $0.50 $1.78
Resistance Level $0.95 $1.89
Average True Range (ATR) 0.07 0.17
MACD -0.01 -0.00
Stochastic Oscillator 0.00 9.26

Price Performance

Historical Comparison
BOXL
GRI

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions, including flat-panels, LED video walls, and digital signage for the enterprise market. It has three reportable segments - Europe, Middle East and Africa (EMEA), and North and Central America (Americas). The majority of revenue is derived from the sale of education technology products in the EMEA segment.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: